Intravenous and Intratracheal Mesenchymal Stromal Cell Injection in a Mouse Model of Pulmonary Emphysema

Abstract

The aim of this study was to characterize the evolution of lung function and -structure in elastase-induced emphysema in adult mice and the effect of mesenchymal stromal cell (MSC) administration on these parameters. Adult mice were treated with intratracheal (4.8 units/100 g bodyweight) elastase to induce emphysema. MSCs were administered intratracheally or intravenously, before or after elastase injection. Lung function measurements, histological and morphometric analysis of lung tissue were performed at 3 weeks, 5 and 10 months after elastase and at 19, 20 and 21 days following MSC administration. Elastase-treated mice showed increased dynamic compliance and total lung capacity, and reduced tissue-specific elastance and forced expiratory flows at 3 weeks after elastase, which persisted during 10 months follow-up. Histology showed heterogeneous alveolar destruction which also persisted during long-term follow-up. Jugular vein injection of MSCs before elastase inhibited deterioration of lung function but had no effects on histology. Intratracheal MSC treatment did not modify lung function or histology. In conclusion, elastase-treated mice displayed persistent characteristics of pulmonary emphysema. Jugular vein injection of MSCs prior to elastase reduced deterioration of lung function. Intratracheal MSC treatment had no effect on lung function or histology.

Human mesenchymal stromal cells exert HGF dependent cytoprotective effects in a human relevant pre-clinical model of COPD

“…Initially this work sought to establish the optimal dose for human MSC therapy in this model. While studies have compared different rodent MSC sources30 and delivery routes3045 this is the first study to demonstrate a dose response. In line with hMSC dose selection based on hMSC/kg weight for human trials, a dose dependency study was performed based on animal weight.…”

Stem cell–based therapies for the newborn lung and brain: Possibilities and challenges

“…The best route remains to be determined but one recent study suggested that IT administration of MSCs was more efficacious that IV using the neonatal rat hyperoxia model 53 . In contrast, IV MSC injection halted lung deterioration whereas IT MSCs had no effect on lung histology or dysfunction in an adult mouse model of elastase-induced emphysema 54 , pointing to potentially disease-specific and age-specific differential responses to the most optimal route for MSC delivery.…”

Human mesenchymal stem cells (MSCs) for treatment towards immune- and inflammation-mediated diseases: review of current clinical trials

“…In asthma, however, mast cells, eosinophils and Th2 lymphocytes are involved in further aggravation of airway hyperresponsiveness and bronchoconstriction [117]. In rodent models of elastase-induced emphysema or cigarette-induced COPD, MSC infusion reduces lung destruction and aberrant inflammation [118, 119]. MSC-secreted epidermal growth factor (EGF) leads to induction of secretory leukocyte protease inhibitor (SLPI), an inhibitor which protects epithelial tissues from serine protease degradation [120, 121].…”